Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ventana warming to Roche deal?

This article was originally published in The Gray Sheet

Executive Summary

Tissue-based cancer test firm Ventana Medical Systems enters into a confidentiality agreement with Roche, allowing the latter firm to begin a due diligence review with an eye toward potentially acquiring Ventana, the firms announce Nov. 13. However, Ventana still believes Roche's current hostile offer of $3 billion ($75 per share) is "grossly inadequate." Roche initiated the offer in June and renewed it for the fourth time last month (1"The Gray Sheet" Nov. 5, 2007, p. 18). Ventana believes that the due diligence and "related discussions" will allow Roche to recognize the "significant additional value inherent in Ventana's business," potentially resulting in a richer offer. However, the likelihood of a deal remains uncertain, both firms say. Ventana stock closed at $90.08 on Nov. 16

You may also be interested in...



Roche’s pursuit of Ventana continues

Roche will seek election of alternative Ventana board members at the latter firm's next annual shareholder meeting, slated for June 2008, as part of an ongoing effort to acquire the cancer test maker, Roche says Dec. 5. The firms entered into a confidentiality agreement Nov. 13 so that Roche could commence a due diligence review of Ventana's business after Roche initiated a hostile $3 billion takeover offer last June (valued at $75 per share). Ventana rejects the offer as inadequate (1"The Gray Sheet" Nov. 19, 2007, In Brief)

Diagnostics In Brief

Siemens/Dade deal: Siemens expects to close its $7 billion acquisition of diagnostics firm Dade Behring Nov. 6, ahead of initial expectations. The announcement follows expiration of the $77 per share cash tender offer on Oct. 31. Dade CEO Jim Reid-Anderson will become the new chief of Siemens Medical Solutions Diagnostics. The division is currently headed by Tony Bihl, former president of Bayer Diagnostics, which Siemens acquired in January. Primary offices will be located at Dade's headquarters in Deerfield, Ill. Dade recently reported third-quarter sales of $475 million, up 12% over the prior-year period. Upon completion of the deal, Siemens is expected to overtake Roche Diagnostics as the in vitro diagnostics market leader (1"The Gray Sheet" July 30, 2007, p. 4)

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

UsernamePublicRestriction

Register

MT025509

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel